After nearly 2 decades, Medacta changes the guard

doctor looking at x-ray of spine
The CEO role remains a family affair for the company. (Getty/cyano66)

Joint replacement and spinal surgery company Medacta International is gaining a new chief executive for the first time in nearly 20 years, but the leadership still remains within the Siccardi family.

The privately owned Swiss firm says that Alberto Siccardi, Medacta’s founder and longtime CEO, is moving upstairs to become president of the board.

In his place, the family-run company will promote its EVP and Alberto Siccardi’s son, Francesco Siccardi, as Medacta’s next leader. The company says in a statement that this change-up “comes as Medacta experiences strong growth, dynamic new product introductions around the world.”


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

“It has been tremendously gratifying to see Medacta’s focus on medical education and sustainability resonate with surgeons and healthcare organizations around the world and to know that, together, we have changed orthopedics for tens of thousands of patients and their families,” said Alberto Siccardi, who founded Medacta following his own experience as a hip replacement surgery patient.

“Medacta’s continued growth and prosperity make this an opportune time to transition to the next generation of the company’s leadership. With a deep understanding of both the technical and commercial sides of our business, Francesco is the right person to lead Medacta into the next phase of its evolution.”

Francesco Siccardi has served as EVP of Medacta International since 2010, is a biomedical engineer by training, and has been at the company since 2002.

“Medacta was borne out of my father’s experience as a patient, when he realized that orthopedic care should and could be better for both patient and surgeon alike. The company’s success is testament to that initial vision, and to the hard work behind it,” said Francesco Siccardi.

“Over the past 20 years, Medacta has opened hundreds of surgeon learning centers, expanded into several new surgical disciplines, supported research efforts around the world and changed the face of orthopedics in the process. The future is bright, and I am ecstatic to lead our talented Medacta team toward it.”

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.